Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
COSTS AND EXPENSES:        
Research and development $ 7,312,504 $ 5,380,190 $ 20,275,004 $ 13,765,846
General and administrative 2,100,956 2,435,296 6,137,760 7,625,391
Total costs and expenses 9,413,460 7,815,486 26,412,764 21,391,237
LOSS FROM OPERATIONS (9,413,460) (7,815,486) (26,412,764) (21,391,237)
OTHER (EXPENSE) INCOME:        
Warrant issuance expense (470,000)   (470,000)  
Loss on revaluation of warrants (3,900,000)   (3,900,000)  
Interest income, net 51,110 4,164 247,925 5,075
Total other income (4,318,890) 4,164 (4,122,075) 5,075
NET LOSS $ (13,732,350) $ (7,811,322) $ (30,534,839) $ (21,386,162)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (1.21) $ (1.28) $ (2.71) $ (3.50)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (1.21) $ (1.28) $ (2.71) $ (3.50)
SHARES USED IN COMPUTING BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 11,308,738 6,110,119 11,277,231 6,110,123
SHARES USED IN COMPUTING DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 11,308,738 6,110,119 11,277,231 6,110,123